bilaterals.org logo
bilaterals.org logo

medicines


TRIPS Waiver: A BIT of a challenge for India
Potential BIT claims by foreign pharmaceutical companies against India for the revocation, suspension or non-enforcement of IPRs could undermine the benefits of a potential TRIPS waiver.
Intellectual property and COVID-19 medicines: why a WTO waiver may not be enough
The COVID-19 pandemic, and the race to make vaccines and other useful technologies more accessible to people around the world, has once again highlighted the tension between intellectual property rights and the promotion of public health.
UK and EU pharma call for medicines to be prioritised in Brexit trade talks
They have both emphasised the need for trade talks to mitigate medicine supply chain disruptions following Brexit.
A new trend in trade agreements: Ensuring access to cancer drugs
People around the world need to be aware of precedents in recent trade agreements and ensure that they also work for access to medicines for their own citizens.
Vietnam courts EU investment in medical and drug supply chains
Vietnam seeks to build on its new free trade agreement with the European Union to expand foreign investment in medical equipment and pharmaceuticals, with the government position the country as an alternative production base to China.
India, US trade deal: New Delhi seeks preferential treatment on drugs, other goods
India is seeking concessions for generic drugs it exports to the United States in return for opening its dairy markets and slashing tariffs on farm goods as the two sides seek to shore up a new trade deal.
Union calls for equal recognition for healthcare workers
The union and its allies also asked the government not to join the Trans-Pacific Partnership, as they view that the restriction of rights to access medicine under the deal would put the country’s public health system in danger.
If the government doesn’t halt trade talks with Trump, it’s learned nothing from coronavirus
The US trade model is not only unpopular with the British public, but it will also make us more vulnerable to future pandemics.
Covid-19: Why India doesn’t need to worry about investor-State dispute settlement claims
In order to halt the spread of the coronavirus pandemic (Covid-19) and to boost the public health care system and preparedness, India has taken several regulatory steps.
The Comprehensive and Progressive Agreement for the Trans-Pacific Partnership: Data exclusivity and access to biologics
The agreement does not promise that the suspended provision on test data rule concerning biological medicines will remain suspended.
Intellectual property rights: Potential implications of the DCFTA for access to medicine
If the intellectual property provisions of the DCFTA are applied, this will have an impact on both the cost of patented medicines and undermine access to affordable medicines.
Can a US-India trade deal permanently alter the way Indians access medicines?
US-India IP engagements since 2006 have served the interests of the US through systematic undermining of the legislative safeguards in the Indian Patents Act.
Trump will insist NHS pays more for drugs in trade deal, says ambassador
Donald Trump will put the interests of corporate America first and demand that the NHS pays higher prices for US drugs in a free-trade deal with the UK, the outgoing British ambassador to Washington said.
Phase 1 US China trade deal: patent provisions
China agreed to extend patent terms for novel drugs "to compensate for unreasonable delays that occur in granting the patent or during pharmaceutical product marketing approvals."
India, Indonesia negotiating economic cooperation agreement
India and Indonesia are set to launch negotiations for a Comprehensive Economic Cooperation Agreement (CECA) to cover economic cooperation while trading in goods, services, and investments.
Blueprint for a human rights impact assessment of the planned comprehensive free trade agreement between EFTA and Mercosur
This study assesses the impact of the EFTA-Mercosur free trade agreement on access to medicines, indigenous rights and women rights.
Biologic exclusivity provision stripped from revised USMCA deal
A provision of the United States-Mexico-Canada Agreement on trade that would have guaranteed 10 years of market exclusivity for biologic drugs was removed.
Mexico sees progress in talks to revise USMCA, says drug protections to ease
Mexico’s government said progress was being made toward revising a new North American trade pact that will sharply reduce protections for biologic drugs.
Trump administration considers loosening drug protections in USMCA
Generic versions of biologic drugs could come to market faster.
How to protect the NHS in a post-Brexit trade deal with the US
There are two solutions to this impending problem, which most political parties could agree to if they are truly committed to protecting the NHS.